5432452026-10-015432452026-10-012026-10-015432452026-10-01in-capmkt:FinancialYear1Member5432452026-10-01in-capmkt:FinancialYear2Member5432452026-10-01in-capmkt:FinancialYear3Member5432452026-10-012026-10-01in-capmkt:FinancialYear1Member5432452026-10-012026-10-01in-capmkt:FinancialYear2Member5432452026-10-012026-10-01in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure543245GLAND PHARMA LIMITEDGLANDNOTLISTEDINE068V01023NewAcquisition (including agreement to acquire)true2026-10-0115:30:002026-10-01GLAND PHARMA LIMITEDListed Entity (self)Gland Pharma USA Inc.0-620000039300000NAtrue2026-10-012026-09-13falsefalsetruePharmaceutical IndustryThe investment of USD 21,000,000 by the Company in Gland USA is being undertaken to facilitate expansion of the Company’s business in the United States of America. Gland USA proposes to utilize the funds to subscribe to 60% of the equity share capital of Novelstar Pharma Inc., a newly incorporated Company in the United States of America, pursuant to which Novelstar Pharma Inc. will become a subsidiary of Gland USA and a step-down subsidiary of the Company.Nofalse31-10-2026Cash2022700000USD 210000002022700000111Background: Gland USA is currently a wholly-owned step-down subsidiary of the Company and proposed to be subsidiary of the Company and is in a similar line of business as the Company. Date of Incorporation: March 07, 2022 Last 3 years’ Turnover: FY26 – NIL FY25 – USD 87,342 FY24 – USD 483,808 Country in which the acquired entity has presence: United States of America2025-202602024-202574000002023-202440400000United States of AmericaBackground: Gland USA is currently a wholly-owned step-down subsidiary of the Company and proposed to be subsidiary of the Company and is in a similar line of business as the Company. Date of Incorporation: March 07, 2022 Last 3 years’ Turnover: FY26 – NIL FY25 – USD 87,342 FY24 – USD 483,808 Country in which the acquired entity has presence: United States of America